Eversept Partners
Latest statistics and disclosures from Eversept Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are UTHR, ABVX, EHC, ENSG, VERA, and represent 29.72% of Eversept Partners's stock portfolio.
- Added to shares of these 10 stocks: ENSG (+$94M), EHC (+$84M), CTRE (+$43M), COGT (+$19M), INSM (+$16M), THC (+$16M), TVTX (+$15M), VKTX (+$14M), AMN (+$14M), CELC (+$13M).
- Started 30 new stock positions in BEAM, PACS, COGT, DSGN, VOR, PRQR, AMN, ASND, ATAI, NHI.
- Reduced shares in these 10 stocks: QQQ (-$103M), , GSK (-$68M), NTRA (-$57M), , QGEN (-$37M), TLT (-$37M), DOC (-$33M), AVTR (-$23M), WELL (-$21M).
- Sold out of its positions in AGIO, AIRS, AVTR, BVS, CNC, DAWN, DHC, Engene Holdings, Enhabit Ord, ESPR.
- Eversept Partners was a net seller of stock by $-172M.
- Eversept Partners has $1.9B in assets under management (AUM), dropping by 1.65%.
- Central Index Key (CIK): 0001697013
Tip: Access up to 7 years of quarterly data
Positions held by Eversept Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Eversept Partners
Eversept Partners holds 119 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| United Therapeutics Corporation (UTHR) | 8.1 | $156M | +8% | 288k | 541.83 |
|
| Abivax Sa Sponsored Ads (ABVX) | 6.3 | $122M | -2% | 914k | 133.26 |
|
| Encompass Health Corp (EHC) | 5.4 | $104M | +429% | 1.0M | 101.08 |
|
| Ensign (ENSG) | 5.0 | $97M | +3978% | 602k | 160.30 |
|
| Vera Therapeutics Cl A (VERA) | 4.9 | $95M | 2.2M | 42.91 |
|
|
| Invesco Qqq Tr Unit Ser 1 Put Option (QQQ) | 3.8 | $73M | -58% | 99k | 736.40 |
|
| Celldex Therapeutics Com New (CLDX) | 3.4 | $67M | 1.8M | 37.21 |
|
|
| Syndax Pharmaceuticals (SNDX) | 3.2 | $61M | -3% | 2.8M | 21.86 |
|
| Brookdale Senior Living (BKD) | 2.8 | $55M | -4% | 3.4M | 16.09 |
|
| Ionis Pharmaceuticals (IONS) | 2.7 | $53M | +5% | 665k | 79.29 |
|
| Natera (NTRA) | 2.5 | $48M | -54% | 176k | 271.45 |
|
| Travere Therapeutics (TVTX) | 2.4 | $45M | +47% | 799k | 56.81 |
|
| Caretrust Reit (CTRE) | 2.2 | $43M | NEW | 1.1M | 40.35 |
|
| Hca Holdings (HCA) | 2.0 | $38M | +24% | 98k | 389.89 |
|
| Vaxcyte (PCVX) | 1.9 | $37M | -31% | 630k | 58.13 |
|
| Liquidia Corporation Com New (LQDA) | 1.8 | $34M | -36% | 429k | 79.73 |
|
| Community Health Systems (CYH) | 1.4 | $26M | -9% | 7.9M | 3.34 |
|
| Insmed Com Par $.01 Call Option (INSM) | 1.4 | $26M | +161% | 246k | 106.62 |
|
| GSK Sponsored Adr (GSK) | 1.3 | $25M | -73% | 482k | 52.42 |
|
| Chemed Corp Com Stk (CHE) | 1.3 | $25M | +69% | 53k | 465.74 |
|
| Eli Lilly & Co. (LLY) | 1.3 | $24M | +5% | 20k | 1199.43 |
|
| Geron Corporation (GERN) | 1.2 | $24M | 19M | 1.28 |
|
|
| Viking Therapeutics (VKTX) | 1.2 | $24M | +152% | 603k | 39.01 |
|
| Omega Healthcare Investors (OHI) | 1.2 | $23M | -17% | 484k | 47.68 |
|
| Insulet Corporation (PODD) | 1.2 | $23M | +3% | 149k | 152.25 |
|
| Tenet Healthcare Corp Com New (THC) | 1.1 | $21M | +286% | 114k | 187.08 |
|
| UnitedHealth (UNH) | 1.1 | $21M | +27% | 51k | 415.63 |
|
| Welltower Inc Com reit (WELL) | 1.0 | $20M | -51% | 87k | 226.97 |
|
| Beta Bionics (BBNX) | 1.0 | $20M | -11% | 1.2M | 15.67 |
|
| Cogent Biosciences (COGT) | 1.0 | $19M | NEW | 490k | 38.70 |
|
| BioCryst Pharmaceuticals (BCRX) | 1.0 | $19M | -38% | 1.9M | 10.00 |
|
| Molina Healthcare (MOH) | 1.0 | $18M | +145% | 81k | 228.70 |
|
| Pennant Group (PNTG) | 0.9 | $17M | +47% | 460k | 36.95 |
|
| LTC Properties (LTC) | 0.8 | $16M | +31% | 421k | 38.45 |
|
| Miragen Therapeutics (VRDN) | 0.8 | $15M | +16% | 831k | 18.37 |
|
| BioMarin Pharmaceutical (BMRN) | 0.7 | $14M | +20% | 250k | 57.22 |
|
| AMN Healthcare Services (AMN) | 0.7 | $14M | NEW | 429k | 32.37 |
|
| Celcuity (CELC) | 0.7 | $13M | NEW | 128k | 104.62 |
|
| Pharvaris N V (PHVS) | 0.7 | $13M | -5% | 386k | 34.58 |
|
| Cytomx Therapeutics (CTMX) | 0.7 | $13M | +11% | 3.6M | 3.75 |
|
| Humana (HUM) | 0.6 | $12M | NEW | 31k | 397.22 |
|
| Xenon Pharmaceuticals (XENE) | 0.6 | $12M | +51% | 197k | 60.36 |
|
| Corvus Pharmaceuticals (CRVS) | 0.6 | $11M | NEW | 748k | 14.94 |
|
| Ascendis Pharma A/s Ord Shs (ASND) | 0.6 | $11M | NEW | 42k | 266.72 |
|
| Bruker Corporation (BRKR) | 0.6 | $11M | +56% | 183k | 60.18 |
|
| Moderna (MRNA) | 0.6 | $11M | -4% | 152k | 70.03 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.5 | $11M | +42% | 196k | 53.67 |
|
| Definium Therapeutics Com Shs (DFTX) | 0.5 | $10M | +35% | 217k | 47.04 |
|
| Compass Pathways Sponsored Ads (CMPS) | 0.5 | $9.5M | 673k | 14.15 |
|
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.5 | $9.3M | -3% | 276k | 33.89 |
|
| PerkinElmer (RVTY) | 0.5 | $9.3M | 84k | 111.26 |
|
|
| Palisade Bio (PALI) | 0.5 | $8.7M | -16% | 4.2M | 2.09 |
|
| Ardelyx (ARDX) | 0.4 | $8.6M | -24% | 1.7M | 5.10 |
|
| Mineralys Therapeutics (MLYS) | 0.4 | $8.4M | NEW | 310k | 26.98 |
|
| Relay Therapeutics (RLAY) | 0.4 | $8.1M | +60% | 434k | 18.71 |
|
| Novo-nordisk A S Adr (NVO) | 0.4 | $8.1M | NEW | 169k | 47.94 |
|
| Biohaven (BHVN) | 0.4 | $7.7M | NEW | 516k | 14.88 |
|
| Protagonist Therapeutics (PTGX) | 0.4 | $7.2M | NEW | 59k | 122.58 |
|
| Enliven Therapeutics (ELVN) | 0.4 | $6.9M | NEW | 137k | 50.75 |
|
| Replimune Group (REPL) | 0.3 | $6.5M | +52% | 590k | 11.07 |
|
| Lb Pharmaceuticals Com Shs (LBRX) | 0.3 | $6.0M | +83% | 184k | 32.45 |
|
| Beam Therapeutics (BEAM) | 0.3 | $5.7M | NEW | 166k | 34.32 |
|
| National Health Investors (NHI) | 0.3 | $5.4M | NEW | 71k | 76.26 |
|
| Ultragenyx Pharmaceutical (RARE) | 0.3 | $5.1M | +146% | 154k | 33.39 |
|
| Pacs Group Com Shs (PACS) | 0.3 | $5.0M | NEW | 117k | 42.64 |
|
| Spdr Series Trust St Str Sp Biot Put Option (XBI) | 0.3 | $4.9M | +3% | 31k | 158.25 |
|
| Equillium (EQ) | 0.3 | $4.9M | 1.5M | 3.20 |
|
|
| Anaptysbio Inc Common (ANAB) | 0.2 | $4.7M | +158% | 70k | 67.50 |
|
| National HealthCare Corporation (NHC) | 0.2 | $4.7M | NEW | 22k | 211.36 |
|
| Eyepoint Com New (EYPT) | 0.2 | $4.3M | NEW | 298k | 14.30 |
|
| Capital Sr Living Corp (SNDA) | 0.2 | $4.2M | +260% | 103k | 40.80 |
|
| Glaukos (GKOS) | 0.2 | $4.1M | -51% | 29k | 139.76 |
|
| Agilon Health Com New (AGL) | 0.2 | $4.1M | -78% | 38k | 107.18 |
|
| Arcutis Biotherapeutics (ARQT) | 0.2 | $3.5M | -76% | 135k | 26.22 |
|
| Tarsus Pharmaceuticals (TARS) | 0.2 | $3.5M | NEW | 56k | 62.94 |
|
| Alto Neuroscience Com Shs (ANRO) | 0.2 | $3.4M | +2% | 128k | 26.39 |
|
| Silverback Therapeutics (SPRY) | 0.2 | $3.0M | +176% | 377k | 8.01 |
|
| Inflarx Nv (IFRX) | 0.2 | $2.9M | -25% | 1.3M | 2.24 |
|
| Intuitive Surgical Com New (ISRG) | 0.1 | $2.9M | -34% | 7.2k | 397.68 |
|
| Alector (ALEC) | 0.1 | $2.9M | +5% | 1.4M | 2.01 |
|
| Universal Hlth Svcs CL B Put Option (UHS) | 0.1 | $2.8M | +3% | 19k | 148.69 |
|
| Vor Biopharma Com New (VOR) | 0.1 | $2.8M | NEW | 150k | 18.41 |
|
| Design Therapeutics (DSGN) | 0.1 | $2.7M | NEW | 190k | 14.47 |
|
| Karyopharm Therapeutics Com New (KPTI) | 0.1 | $2.7M | -7% | 276k | 9.77 |
|
| Qiagen Nv Ord Shares Call Option (QGEN) | 0.1 | $2.7M | -93% | 68k | 39.10 |
|
| Pmv Pharmaceuticals (PMVP) | 0.1 | $2.5M | -19% | 1.9M | 1.34 |
|
| Contineum Therapeutics Cl A (CTNM) | 0.1 | $2.4M | 148k | 16.39 |
|
|
| Evommune Com Shs (EVMN) | 0.1 | $2.3M | +219% | 175k | 13.29 |
|
| Amarin Corp Sponsored Adr (AMRN) | 0.1 | $2.3M | 145k | 15.94 |
|
|
| Spruce Biosciences Com New (SPRB) | 0.1 | $2.2M | NEW | 40k | 54.00 |
|
| Repligen Corporation (RGEN) | 0.1 | $2.0M | -88% | 14k | 136.44 |
|
| Adagio Therapeutics (IVVD) | 0.1 | $2.0M | 2.2M | 0.87 |
|
|
| Proqr Thrapeutics N V Shs Euro (PRQR) | 0.1 | $1.9M | NEW | 1.0M | 1.86 |
|
| Acasti Pharma (GRCE) | 0.1 | $1.8M | +2% | 773k | 2.27 |
|
| Anteris Technologies Global (AVR) | 0.1 | $1.6M | -58% | 166k | 9.85 |
|
| Vir Biotechnology (VIR) | 0.1 | $1.6M | -37% | 157k | 10.19 |
|
| Editas Medicine (EDIT) | 0.1 | $1.5M | +57% | 459k | 3.24 |
|
| Aadi Bioscience (WHWK) | 0.1 | $1.4M | 303k | 4.58 |
|
|
| Bio-techne Corporation (TECH) | 0.1 | $1.4M | -84% | 19k | 70.65 |
|
| Revolution Medicines (RVMD) | 0.1 | $1.3M | NEW | 6.9k | 187.28 |
|
| Savara (SVRA) | 0.1 | $1.3M | -46% | 204k | 6.16 |
|
| Surrozen Com New (SRZN) | 0.1 | $1.2M | -18% | 48k | 25.95 |
|
| Inovio Pharmaceuticals Com Shs (INO) | 0.1 | $1.1M | 1.0M | 1.10 |
|
|
| Pliant Therapeutics (PLRX) | 0.1 | $1.0M | 891k | 1.14 |
|
|
| Cybin Com New (HELP) | 0.1 | $968k | NEW | 146k | 6.61 |
|
| Odyssey Therapeutics Common Stock | 0.0 | $929k | NEW | 50k | 18.71 |
|
| Engene Therapeutics (ENGN) | 0.0 | $812k | NEW | 470k | 1.73 |
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 0.0 | $809k | 191k | 4.24 |
|
|
| Lipocine Com New (LPCN) | 0.0 | $755k | 295k | 2.56 |
|
|
| Relmada Therapeutics (RLMD) | 0.0 | $645k | -66% | 93k | 6.92 |
|
| eHealth (EHTH) | 0.0 | $603k | +83% | 405k | 1.49 |
|
| Ataibeckley Com Shs (ATAI) | 0.0 | $540k | NEW | 102k | 5.27 |
|
| Akebia Therapeutics (AKBA) | 0.0 | $487k | NEW | 427k | 1.14 |
|
| Ss Innovations International Com New (SSII) | 0.0 | $457k | 110k | 4.15 |
|
|
| Assembly Biosciences Com New (ASMB) | 0.0 | $454k | -59% | 17k | 27.48 |
|
| Retractable Technologies (RVP) | 0.0 | $418k | 581k | 0.72 |
|
|
| Selectquote Ord (SLQT) | 0.0 | $269k | -10% | 320k | 0.84 |
|
| Gh Research Ordinary Shares (GHRS) | 0.0 | $233k | NEW | 8.7k | 26.88 |
|
| Avalo Therapeutics Com New (AVTX) | 0.0 | $185k | NEW | 10k | 18.48 |
|
Past Filings by Eversept Partners
SEC 13F filings are viewable for Eversept Partners going back to 2017
- Eversept Partners 2026 Q2 filed Aug. 14, 2026
- Eversept Partners 2026 Q1 filed May 15, 2026
- Eversept Partners 2025 Q4 filed Feb. 17, 2026
- Eversept Partners 2025 Q3 filed Nov. 14, 2025
- Eversept Partners 2025 Q2 filed Aug. 14, 2025
- Eversept Partners 2025 Q1 filed May 15, 2025
- Eversept Partners 2024 Q4 filed Feb. 14, 2025
- Eversept Partners 2024 Q3 filed Nov. 14, 2024
- Eversept Partners 2024 Q2 filed Aug. 14, 2024
- Eversept Partners 2024 Q1 filed May 15, 2024
- Eversept Partners 2023 Q4 filed Feb. 14, 2024
- Eversept Partners 2023 Q3 filed Nov. 14, 2023
- Eversept Partners 2017 Q4 restated filed Nov. 8, 2023
- Eversept Partners 2018 Q1 restated filed Nov. 8, 2023
- Eversept Partners 2018 Q2 restated filed Nov. 8, 2023
- Eversept Partners 2018 Q3 restated filed Nov. 8, 2023